LANTHEUS HOLDINGS,INC. (NASDAQ:LNTH) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On May2, 2017, Lantheus Holdings, Inc. (the Company) announced
via press release its financial results as of and for the three
months ended March31, 2017.A copy of that press release is being
furnished as Exhibit 99.1 and is hereby incorporated by
reference.
The information furnished to this Item2.02, including Exhibit
99.1, shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities under that Section and
shall not be deemed to be incorporated by reference into any
filing of the Company under the Securities Act of 1933, as
amended, or the Exchange Act.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1* |
Press release of Lantheus Holdings, Inc. dated May2, 2017, entitled Lantheus Holdings, Inc. Reports 2017 First Quarter Financial Results; Exceeds First Quarter and Raises Full-Year 2017 Guidance |
| * |
Exhibit 99.1 attached hereto is being furnished and shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. |
About LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH)
Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals. LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH) Recent Trading Information
LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH) closed its last trading session down -0.50 at 12.90 with 466,533 shares trading hands.